Sobi Announces Impressive Financial Performance for 2025
STOCKHOLM – Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) has revealed that its revenue and adjusted EBITA margin surpassed previous forecasts for 2025. The company reported a full-year revenue of approximately SEK 28.2 billion, reflecting a substantial growth of about 15 percent at a constant exchange rate.
Boost in Revenue Driven by Strong Sales
The impressive revenue growth can be attributed primarily to higher-than-expected sales in the fourth quarter, particularly for key products like Doptelet, Gamifant, and the Haemophilia portfolio. These products have shown remarkable resilience in demand, showcasing Sobi's ability to capitalize on market potential effectively.
Adjustments to EBITA Margin
The adjusted EBITA margin for Sobi was recorded at approximately 40 percent of revenues, exceeding prior projections. This improvement in margins reflects the company’s ongoing efforts to enhance operational efficiencies and maximize profitability in light of its robust sales performance.
Looking Back at Fiscal Year 2025
Initially, at the time of the third-quarter report published in October 2025, Sobi projected a modest revenue growth in low double digits at a constant exchange rate. The company also anticipated its adjusted EBITA margin to be within the mid to high-30s percent of revenue. The overwhelming results indicate that Sobi not only met but exceeded these expectations, underlining its strong market positioning.
Upcoming Financial Announcements
Sobi will continue to keep stakeholders informed by releasing its fourth quarter and full year 2025 financial report on February 5, 2026, at 8:00 AM CET. This upcoming report is likely to provide deeper insights into the company’s financial health and strategies moving forward.
About Sobi
Sobi is a prominent global biopharma entity focused on harnessing groundbreaking innovations. The company is committed to transforming the lives of individuals living with rare diseases. With a workforce of around 1,900 employees spread across Europe, North America, the Middle East, Asia, and Australia, Sobi is well-equipped to drive its mission forward. In 2024, the company reported revenue of SEK 26 billion, and its shares are listed on NASDAQ Stockholm.
Contact Information
For inquiries regarding investor relations, stakeholders can reach out to Sobi’s team through the appropriate channels available on their website. For media-related inquiries, the media relations team is also accessible via the same online resources.
This announcement is deemed public information as per regulatory requirements, ensuring transparency and accountability in communications with the market.
Frequently Asked Questions
What was Sobi's revenue for the year 2025?
Sobi reported approximately SEK 28.2 billion in revenue for the year 2025.
What contributed to Sobi's revenue growth?
The significant revenue growth was primarily driven by higher-than-expected sales of key products like Doptelet and Gamifant.
What was the adjusted EBITA margin for Sobi in 2025?
Sobi's adjusted EBITA margin for 2025 was approximately 40 percent of revenues.
When will Sobi announce its fourth-quarter results?
Sobi is set to announce its fourth-quarter and full-year results on February 5, 2026.
How many employees does Sobi have?
Sobi employs around 1,900 individuals worldwide in various regions including Europe and North America.
